News Conference News AHA 2025 POLY-HF: Polypill Pays Dividends in Patients With HFrEF Todd Neale November 14, 2025
News Daily News Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors Yael L. Maxwell August 15, 2024
News Conference News AHA 2023 Seeing Sticker Price for HFrEF Meds Opens Door to Discussions Caitlin E. Cox November 14, 2023
News Daily News First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists L.A. McKeown August 31, 2023
News Daily News Vast Majority of HFrEF Patients Eligible for Vericiguat L.A. McKeown February 08, 2023
News Daily News Quadruple Therapy Costs Prohibitive for Many HFrEF Patients L.A. McKeown June 21, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Daily News Did Regional Differences Muddy Results in COMMANDER-HF? L.A. McKeown February 04, 2021
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019